2006
DOI: 10.1590/s0004-27302006000400020
|View full text |Cite
|
Sign up to set email alerts
|

Update on osteoporosis therapy

Abstract: Osteoporosis is a skeletal disorder characterized by compromised bone strength that predisposes a person to increased fracture risk. Fractures are often associated with increased morbidity, higher mortality, loss of function and even psychological consequences. Pharmacotherapeutic interventions (e.g., bisphosphonates, selective estrogen receptor modulators, calcitonin, and teriparatide) in women with postmenopausal osteoporosis provide substantial reduction in fracture risk over and above risk reduction with c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
2
0

Year Published

2008
2008
2020
2020

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 12 publications
(3 citation statements)
references
References 36 publications
0
2
0
Order By: Relevance
“…The resulting bone loss is associated with increased fractures, morbidity, and mortality [1]. During the past 20 years, several new pharmacologic therapies, including antiresorptive (anti-remodeling) agents that are potent inhibitors of osteoclast activity and anabolic therapies that stimulate bone formation, have been developed for the treatment of this disease [2][3][4].…”
Section: Introductionmentioning
confidence: 99%
“…The resulting bone loss is associated with increased fractures, morbidity, and mortality [1]. During the past 20 years, several new pharmacologic therapies, including antiresorptive (anti-remodeling) agents that are potent inhibitors of osteoclast activity and anabolic therapies that stimulate bone formation, have been developed for the treatment of this disease [2][3][4].…”
Section: Introductionmentioning
confidence: 99%
“…The resulting bone loss is associated with increased fractures, morbidity, and mortality [1]. During the past 20 years, several new pharmacologic therapies, including anti-resorptive (antiremodeling) agents that are potent inhibitors of osteoclast activity and anabolic therapies that stimulate bone formation, have been developed for the treatment of this disease [2][3][4].…”
Section: Introductionmentioning
confidence: 99%
“…Osteoporosis is a disease that causes a reduction in bone density that occurs when adequate amounts of calcium are not taken, an element contained mainly in milk and derived products. Without the right calcium intake, one of the main constituents of bone tissue would be missing [76][77][78][79].…”
Section: Food and Drugsmentioning
confidence: 99%